Essential thrombocythemia in children.

Area of Science:

• Pediatric Hematology
• Oncology
• Thrombotic Disorders

Background:

• Essential thrombocythemia (ET) is a rare myeloproliferative neoplasm.
• Understanding the clinical presentation and outcomes in pediatric ET is crucial for management.

Purpose of the Study:

• To evaluate the clinical course, laboratory findings, and outcomes of children diagnosed with essential thrombocythemia.
• To identify factors associated with complications and disease progression in pediatric ET.

Main Methods:

• A retrospective analysis of 36 children (6 weeks to 18 years) with ET.
• Combined institutional data with a review of 34 reported cases from English medical literature.

Main Results:

• Fifteen patients experienced ET-related symptoms, including severe thrombohemorrhagic phenomena in nine.
• Abnormalities included large platelets, increased megakaryocytes, and altered platelet aggregation.
• Symptomatic patients had higher platelet counts, but thrombotic events occurred even with moderate elevations.
• Leukemia and myelofibrosis were observed in treated patients; fatalities resulted from leukemia or thrombosis.
• Forty-seven percent of cases were familial, presenting with lower platelet counts and no thrombotic complications.

Conclusions:

• A significant number of children with ET develop severe vascular complications.
• Platelet counts correlate with complications but are not always predictive.
• Current treatment indications and optimal management strategies for pediatric ET are unknown, necessitating guideline development.
• Familial thrombocythemia in children appears to be a distinct entity with a more favorable prognosis.